期刊文献+

不同来源HL60细胞用于调理吞噬杀菌试验的比较 被引量:1

Comparison of opsonophagocytic killing capacity against Streptococcus pneumonia by HL60 cells between two different sources
暂未订购
导出
摘要 目的通过比较不同来源的HL60细胞分化后细胞的表面标志、活性及其对肺炎链球菌调理吞噬杀菌指数的动态变化,评价HL60细胞的来源对肺炎链球菌调理吞噬杀菌能力的影响。方法使用流式细胞仪连续监测来源于美国ATCC和中国科学院上海细胞研究所的HL60细胞在分化后1~7d的表面标志CDllb、CD35和CD71的表达情况,并观察活细胞、凋亡细胞和死亡细胞的比例;同时使用两种不同来源的细胞检测09CS和B两份质控血清对肺炎链球菌血清型6B、7F、14和23F菌株的调理吞噬杀菌指数,同时观察09CS对13价结合疫苗血清型1、3、4、5、6A、6B、7F、9V、14、18C、19A、19F和23F菌株的调理吞噬杀菌指数。结果两种不同来源HL60细胞分化3~6d细胞的表面标志、活细胞比例均可达到国际实验室的要求指标;两份质控血清对检测菌株的调理吞噬杀菌指数均能稳定于质控范围之内;两种细胞检测的09CS对13价肺炎链球菌结合疫苗血清型菌株的调理吞噬杀菌指数具可比性。结论两种来源不同的HL60细胞分化3-6d均能用于评价肺炎链球菌疫苗免疫血清的调理吞噬杀菌试验,这为调理吞噬杀菌试验及其标准化在国内的建立提供了便利。 Objective To assess the influence of HL60 cells purchased from different sources on the opsonophagocytic kill- ing capacity against Streptococcus pneumonia by comparison of the expression of surface markers, cell viability and opsonic index. Methods The cell surface markers of CD1 lb, CD35, CD71 and cell viability of differentiated HL60 cells were daily monitored for 1-7 days after induction with DMF ( N, N-Dimethyl formamide ) by using flow cytometer. Opsonophagocytic killing assay (OPKA) were simultaneously performed against pneumococcal strains of serotype 6B, 7F, 14 and 23F with 2 quality control sera 09CS and B as well as against strains of 13 valent conjugate vaccine serotype 1,3,4,5,6A, 6B, 7F, 9V,14, 18C, 19A, 19F and 23F with 09CS, by using differentiated HL60 cell from different sources. Results During 3- 6 days after differentiation, irrespective of HL60 cell sources, the expression of CD11 b, CD35, CDT1 and cell viability of differentiated HL60 cells met the essential criteria cited among international laboratories, and the opsonic indexes ( OI ) tested for given strains were stable and fell within the ranges well established for quality controls. Conclusions HL60 cells from both ATCC and Shanghai can be used in OPKA for evaluation of pneumococcal vaccine, which will facilitate the estab- lishment and standardization of OPKA in domestic.
出处 《微生物学免疫学进展》 2013年第6期1-6,共6页 Progress In Microbiology and Immunology
基金 国家科技支撑计划2008BAI66B01<细菌多糖蛋白结合关键技术及其应用研究>
关键词 HL60细胞 分化 细胞表面标志 肺炎链球菌 调理吞噬杀菌试验 HL60 cell Differentiation Cell surface markers Streptococcus pneumonia Opsonophagocytic killing assay ( OPKA )
  • 相关文献

参考文献10

  • 1J砮dar L;Butler J;Carlone G.Serological criteria for evalu-ation and licensure of new pneumococcal conjugate vaccine formu-lations for use in infants[J],{H}VACCINE2003(23):3265-3272.
  • 2Wernette CM,Frasch CE,Madore DV. Enzyme-linked im-munosorbent assay for quanti tation of human antibodies to pneu-mococcal polysaccharides[J].{H}Clinical and Diagnostic Laboratory Immunology,2003,(04):514-519.
  • 3Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older[J].{H}Morbidity and Mortality Weekly Report,2012,(21):394-395.
  • 4Rose CE,Romero-Steiner S,Burton RL. Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of func-tional antibody activity in human reference sera[J].{H}Clinical and Vaccine Immunology,2011,(01):135-142.
  • 5Romero-Steiner S,Frasch CE,Carlone G. Use of opsonoph-agocytosis for serological evaluation of pneumococcal vaccines[J].{H}Clinical and Vaccine Immunology,2006,(02):165-169.
  • 6Collins SJ,Gallo RC,Gallagher RE. Continuous growth and dif-ferentiation of human myeloid leukaemic cells in suspension cul-ture[J].{H}NATURE,1977,(5635):347-349.
  • 7World Health Organization. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines[J].{H}WHO TECHNICAL REPORT SERIES,2005,(02):64-98.
  • 8O'Brien KL,Moulton LH,Reid R. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children:group randomised trial[J].{H}LANCET,2003,(9381):355-361.
  • 9Lee H,Nahm MH,Burton R. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vac-cine-related serotypes 6A and 19A[J].{H}Clinical and Vaccine Immunology,2009,(03):376-381.
  • 10王浩,乔瑞洁,史晓玲,林纪胜,谢贵林,赵志强.HL-60分化细胞表面标志、活性及其对肺炎链球菌调理吞噬杀菌能力的动态变化[J].微生物学免疫学进展,2012,40(5):10-14. 被引量:7

二级参考文献14

  • 1World Health Organization.Pneumococcal conjugate vaccines.Recommendations for the production and control of pneumococcalconjugate vaccines[R].WHO Technical Report Series 2005:927(Annex 2):64-98.
  • 2O'Brien KL,Moulton LH,Reid R,et al.Efficacy and safety ofseven-valent conjugate pneumococcal vaccine in American Indianchildren:group randomised trial[J].Lancet,2003;362(9381):355-361.
  • 3Cutts FT,Zaman SM,Enwere G,et al.Efficacy of nine-valentpneumococcal conjugate vaccine against pneumonia and invasivepneumococcal disease in the Gambia:randomised,double-blind,placebo-controlled trial[J].Lancet,2005;365(9465):1139-1146.
  • 4Jódar L,Butler J,Carlone G,et al.Serological criteria for evalua-tion and licensure of new pneumococcal conjugate vaccine formula-tions for use in infants[J].Vaccine,2003,21(23):3265-3272.
  • 5Licensure of 13-valent pneumococcal conjugate vaccine for adultsaged 50 years and older.MMWR,2012,61(21):394.
  • 6Wernette CM,Frasch CE,Madore DV,et al.Enzyme-linked im-munosorbent assay for quanti-tation of human antibodies to pneu-mococcal polysaccharides[J].Clin Diagn Lab Immunol,2003,10(4):514-519.
  • 7Lee H,Nahm MH,Burton R,et al.Immune Response in Infantsto the heptavalent Pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A[J].Clinical and vaccine immunolo-gy,2009,16(3):376–381.
  • 8Romero-Steiner S,Frasch CE,Carlone G,et al.Use of opsonoph-agocytosis for serological evaluation of pneumococcal vaccines[J].Clin Vaccine Immunol,2006,13(2):165-169.
  • 9Collins SJ,Gallo R C,Gallagher RE.Continuous growth and dif-ferentiation of human myeloid leukaemic cells in suspension culture[J].Nature,1977,270(5635):347-349.
  • 10Rose CE,Romero-Steiner S,Burton RL,et al.Multilaboratorycomparison of Streptococcus pneumoniae opsonophagocytic killingassays and their level of agreement for the determination of func-tional antibody activity in human reference sera[J].Clin VaccineImmunol,2011,18(1):135-142.

共引文献6

同被引文献5

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部